Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1

Journal of Interferon and Cytokine Research

Volumn 20, Issue 4, 2000, Pages 349-354

  Xiang, Jim ^a   Moyana, Terence ^a  

^a Saskatoon Cancer Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; CELL DIVISION; CYTOKINES; FEMALE; GENETIC VECTORS; GROWTH INHIBITORS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; REMISSION INDUCTION; TH1 CELLS; TH2 CELLS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0034018521     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999000312270     Document Type: Article

References (26)

1. 1. Desmedt, M., Rottiers, P., Dooms, H., Fiers, W., and Grooten, J. (1998). Macrophages induce cellular immunity by activating Th1 responses and suppressing Th2 responses. J. Immunol. 160, 5300-5308.
2. 2. Mosmann, T., and Sad, S. (1996). The expanding universe of T cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146.
3. 3. Boon,T., Cerottini, J.-C., Vandeneynde,B., Van Der Bruggen, P., and Van Pel, A. (1994). Tumor-antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365.
4. 4. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, D., Robbins, P. Sette, A., Appella, E., and Rosenberg, S. (1995). Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961-3968.
5. 5. Robbins, P., Li, Y., Topalian, S., Rivoltini, L., Sakaguchi, K., Appella, E., Kawakami, Y., and Rosenberg, S. (1995). Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol. 154, 5944-5950.
6. 6. Schwarts, R. (1992). Costimulation of T lymphocytes: the role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065-1071.
7. 7. Gajewski, T., Fallarino, F., Uyttenhove, C., and Boon, T. (1996). Tumor rejection requires a CTLA4 ligand provided by the hose or expressed on the tumor. J. Immunol. 156, 2909-2917.
8. 8. Dranoff, G., and Mulligan, R. (1995). Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454.
9. 9. Pardoll, D. (1995). Paracrine cytokine adjuvants in cancer immuno-therapy. Annu. Rev. Immunol. 113, 399-415.
10. 10. Tsung, K., Meko, J., Peplinski, G., Tsung, Y., and Norton, J. (1997). IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158, 3359-3365.
11. 11. Aruga, A., Aruga, K., Tanigawa, D., Bishop, V., Sondak, K., and Chang, A. (1997). Type 1 vs type 2 cytokine release by V β T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159, 664-673.
12. 12. Lowes, M., Bishop, G., Crotty, K., and Barnetson, R. (1997). T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol. 108, 914-919.
13. 13. Xiang, J., Qi, Y., and Chen, Y. (1997). Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF-α. Cancer Gene Ther. 4, 353-358.
14. 14. Qi, Y., Moyana, T., Chen, Y., and Xiang, J. (1996). Characterization of antitumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-γ. Hum. Antib. 7, 21-26.
15. 15. Xiang, J., Moyana, T., and Qi, Y. (1997). Genetic engineering of a recombinant fusion protein possessing antitumor Fab and tumor necrosis factor. J. Biotech. 53, 3-12.
16. 16. Qi, Y., Chen, Y., and Xiang, J. (1996). Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J. Interferon Cytokine Res. 16, 771-776.
17. 17. Allione, A., Consalvo, M., and Manni, P. (1994). Immunizing and curative potential of replicating and non-replicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF, GMCSF and IFN gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
18. 18. Croft, M., Carter, I., Swain, S., and Dutton, R. (1994). Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180, 1715-1728.
19. 19. Nakamura, T., Lee, S., Nam, E., Podack, K., Bottomly, K., and Flavell, R. (1997). Roles of IL-4 and IFN in stablizing the T helper cell type 1 and 2 phenotype. J. Immunol. 158, 2648-2653.
20. 20. Freeman, G., Bousiotis, V., Anumanthan, A., Berstein G., Ke, X., Rennert, P., Gray, G., Gribben, G., and Nadler, L. (1995). B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523-532.
21. 21. Kuchroo, V., Das, M., Brown, J., Ranger, A., Zamvil, S., Sobel, R., Weiner, H., Nabavi, N., and Glimcher, L. (1995). B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathway: application to autoimmune disease therapy. Cell 80, 707-718.
22. 22. Ghosh, P., Komschies, K., Cippitelli, M., Longo, D., Subleski, J., Ye, J., Sica, A., Young, H., Wiltrout, R., and Ochoa, A. (1995). Gradual loss of Th 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 87, 1478-1483.
23. 23. Khar, A., Kausalya, S., and Kamal, M. (1996). AK-5 tumor-induced modulation of host immune function: upregulation of Th1-type cytokine response mediates early tumor regression. Cytokine Mol. Ther. 2, 39-46.
24. 24. Hu, H., Urba, W., and Fox, B. (1998). Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from type 2 to a type 1 cytokine profile. J. Immunol. 161, 3033-3041.
25. 25. Lee, P., Zeng, D., McCaulay, A., Chen, Y., Geiler, C., Umetsu, D., and Chao, N. (1997). T helper 2-dominant anti-lymphoma immune response is associated with fatal outcome. Blood 90, 1611-1617.
26. 26. Rocken, M., and Shevach, E. (1996). Immune deviation: the third dimension of nondeletional T cell tolerance. Immunol. Rev. 149, 175-194.